MAESTRO 8 [2016/22/A/NZ2/00184]
  1. Suszynska M, Machowska M, Fraszczyk E, Michalczyk M, Philips A, Galka-Marciniak P, Kozlowski P. CMC: Cancer miRNA Census – a list of cancer-related miRNA genes.
    Nucleic Acids Research 2024.
    http://doi: 10.1093/nar/gkae017

  2. Machowska M, Galka-Marciniak P, Kozlowski P. Consequences of genetic variants in miRNA genes.
    Computational and Structural Biotechnology Journal 2022.

  3. Lewandowski K, Kanduła Z, Gniot M, Paczkowska E, Nawrocka PM, Wojtaszewska M, Janowski M, Mariak M, Handschuh L, Kozlowski P. Essential thrombocythaemia in progression to the fibrotic phase is associated with the decrease in JAK2 and PDL1 levels. Ann Hematol. 2022 Oct 21.
    Annals of Hematology 2022.
    http:// 10.1007/s00277-022-05001-8 

  4. Galka-Marciniak P, Kandula Z, Tire A, Wegorek W, Gwozdz-Bak K, Handschuh L, Giefing M, Lewandowski K, Kozlowski P. Mutations in the mir-142 gene are not common in myeloproliferative neoplasms.
    Scientific Reports 2022.

  5. Urbanek-Trzeciak MO, Kozlowski P, Galka-Marciniak P. miRMut: Annotation of mutations in miRNA genes from human whole-exome or whole-genome sequencing.
    STAR Protocols

  6. Nawrocka PM, Galka-Marciniak P, Urbanek-Trzeciak MO, M- Thirusenthilarasan I, Szostak N, Philips A, Susok L, Sand M and Kozlowski P. Profile of basal cell carcinoma mutations and copy number alterations -focus on gene-associated noncoding variants.
    Frontiers in Oncology 2021. 

  7. Suszynska M, Ratajska M, Galka-Marciniak PM, Ryszkowska A, Wydra D, Debniak J, Jasiak A, Wasag B, Cybulski C, Kozlowski P. Variant identification in BARD1, PRDM9, RCC1, and RECQL in patients with ovarian cancer by targeted next-generation sequencing of DNA pools.
    Cancer Prevention Research 2021.   

  8. Galka-Marciniak P, Urbanek-Trzeciak MO, Nawrocka PM, Kozlowski P. A pan-cancer atlas of
    somatic mutations in miRNA biogenesis genes.
    Nucleic Acids Research 2021.  
    The article distinguished by the NAR editors as a Breakthrough article for its originality, significance, and scientific excellence.   

  9. Suszynska M, Kozlowski P. Summary of BARD1 Mutations and Precise Estimation of Breast and Ovarian Cancer Risks Associated with the Mutations.
    Genes (Basel) 2021.   

  10. Urbanek-Trzeciak MO, Galka-Marciniak P, Nawrocka PM, Kowal E, Szwec S, Giefing M, Kozlowski P. Pan-cancer analysis of somatic mutations in miRNA genes.
    EBioMedicine 2020.  

  11. Suszynska M, Ratajska M, Kozlowski P. BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: mutation prevalence and precise risk estimates based on a pooled analysis of ~30,000 cases.
    Journal of Ovarian Research 2020.   

  12. Galka-Marciniak P, Urbanek-Trzeciak MO, Nawrocka PM, Dutkiewicz A, Giefing M, Lewandowska MA, Kozlowski P. Somatic mutations in miRNA genes in lung cancer – potential functional consequences of non-coding sequence variants.
    Cancers 2019.   

  13. Suszynska M, Klonowska K, Jasinska AJ, Kozlowski P. Large-scale meta-analysis of mutations identified in panels of breast/ovarian cancer-related genes - Providing evidence of cancer predisposition genes.
    Gynecologic Oncology 2019 .   

  14. Suszynska M, Kluzniak W, Wokolorczyk D, Jakubowska A, Huzarski T, Gronwald J, Debniak T, Szwiec M, Ratajska M, Klonowska K, Narod S, Bogdanova N, Dörk T, Lubinski J, Cybulski C, Kozlowski P. BARD1 is A Low/Moderate Breast Cancer Risk Gene: Evidence Based on An Association Study of the Central European p.Q564X Recurrent Mutation.
    Cancers (Basel) 2019.

  15. Dabrowska M, Czubak K, Juzwa W, Krzyzosiak WJ, Olejniczak M, Kozlowski P.
    Nucleic Acids Research 2018.
    http://doi: 10.1093/nar/gky505